ArticleOncology letters2025
Prognostic value of inflammation- and nutrition-based biomarkers in patients with recurrent or metastatic oral squamous cell carcinoma treated with immune checkpoint inhibitors: A retrospective study.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic value of inflammation- and nutrition-based biomarkers in oral squamous cell carcinoma (OSCC) remains unclear. The present study evaluated the prognostic significance of these biomarkers in patients with recurrent or metastatic OSCC (R/M-OSCC) undergoing immune checkpoint inhibitor (ICI) therapy. The retrospective study analyzed 45 patients with R/M-OSCC who were treated with ICIs at Hiroshima University Hospital (Hiroshima, Japan) between October 2017 and December 2024. Clinical and treatment data were collected alongside inflammation-based prognostic scores (IBPSs). These biomarkers were calculated prior to and 4-6 weeks after ICI initiation. The 1- and 2-year overall survival (OS) rates for patients were 40 and 22%, respectively, with a median OS of 8.1 months [95% confidence interval (CI): 5.2-14.2). The 1- and 2-year progression-free survival (PFS) rates for patients were 34 and 6.7%, respectively (median PFS, 5.3 months; 95% CI: 2.7-7.9). Post-treatment biomarkers demonstrated superior prognostic value compared with pre-treatment values. Male sex [hazard ratio (HR)=4.11, P=0.0059] and lower body mass index (HR=3.33, P=0.0188) were significantly associated with poorer OS. Post-treatment neutrophil-to-lymphocyte ratio (NLR) (HR=4.17, P=0.0337) and prognostic nutritional index (PNI) (HR=3.92, P=0.0073) were significantly associated with OS. Post-treatment NLR (HR=3.80, P=0.0339), lymphocyte-to-monocyte ratio (LMR) (HR=4.02, P=0.0304) and PNI (HR=2.96, P=0.0342) were significantly associated with PFS. Furthermore, post-treatment IBPS markers, including NLR (P=0.0006), LMR (P=0.0065), platelet-to-lymphocyte ratio (P=0.0396), C-reactive protein-to-albumin ratio (P=0.0062), PNI (P=0.0358) and lymphocyte counts (P=0.0321), were significantly associated with the disease control rate. In conclusion, post-treatment inflammation- and nutrition-based biomarkers could help clinicians identify early those patients most likely to benefit from ICIs and support the development of individualized treatment strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.